Patent · US Active

NK1 antagonists

US9969711B2 · kind B2 · utility

0Cited by

14References

6Claims

0Family size

Assignee

OPKO Health, Inc. · US

Inventors

Anandan Palani · Bound Brook, US
Xianhai Huang · Hackettstown, US
Dong Xiao · Hackettstown, US
Sunil Paliwal · Manalapan, US
Hon-Chung Tsui · East Brunswick Township, US
Michelle Laci Wrobleski · Whitehouse Station, US
Ashwin U. Rao · Avenel, US
Cheng Wang · Fort Washington, US
Sapna S. Shah · Jamesburg, US
Neng-Yang Shih · Lexington, US

Key dates

Filing date	Oct 14, 2016
Grant date	May 15, 2018
Priority date	—
Expiry date	Oct 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A compound having the general structure shown in Formula I:or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.